?
?
1. Evans, E.K., Tester, R., Aslanian, S. et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28
2. Daniel W Pierce*,1, Sabine Ponader, PhD*,2, Kumudha Balakrishnan*,3, Varsha Gandhi, PhD3, William G. Wierda, MD*,4, Susan O'Brien, MD5, Carla Heise, PhD1, Mariana Nacht, PhD*,6, Sharon Aslanian*,6, Xiping Liu*,1, Sean Hong*,1, Shijuan Wu*,1, Marianna Zavodovskaya, MS*,1, Jeffrey Marine*,7, Evelyn Barnett*,7, Pilar Nava-Parada*,7, Jay Mei, MD7, Rajesh Chopra, MD7, Jan A. Burger, MD, PhD4, and Juswinder Singh*,6 Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton's Tyrosine Kinase (Btk) Inhibitor CC-292.November 15, 2013; Blood: 122 (21)
3. Mamluk R1, Carvajal IM, Morse BA, Wong H, Abramowitz J, AslanianS, Lim AC, Gokemeijer J, Storek MJ, Lee J, Gosselin M, Wright MC, Camphausen RT, Wang J, Chen Y, Miller K, Sanders K, Short S, Sperinde J, Prasad G, Williams S, Kerbel R, Ebos J, Mutsaers A, Mendlein JD, Harris AS, Furfine ES.Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs. 2010 Mar 25; 2(2)
4. Aslanian, S., Azimi, M., Noble, J., Hoppe, C. Application of flow cytometry-based genotyping for rapid detection of hemoglobin variants. Int J Lab Hematol. 2007 Aug;29(4):284-91 Malmuk et al.,
Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.
Companies Worked For:
School Attended
Job Titles Held:
Degrees
© 2021, Bold Limited. All rights reserved.